NEW

Switch to Dark

Pricing

Learn

BSX - Boston Scientific Corp

119

$71.20

$1.41 (2.020%)

At market close

$71.50

$0.30 (0.418%)

After Hours 3/17/26, 10:45 PM

4.04/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BSX

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Key Data & Metrics

Market Cap

$105.65B

Industry

Health Care

EPS (TTM)

$1.93

P/E (TTM)

36.46

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

5.26

P/B

4.36

Diluted Shares

1.50B

Ex-Dividend

--

Next Earnings

04-21

Forward P/E

20.41

Payout Ratio

--

P/FCF (TTM)

28.88

FCF Yield

3.46%

Earnings Yield

2.74%

52 Week Range

Score Card

Explore Scores Tab

4.04

Good

Boston Scientific Corp has grown revenue at 19.88% over the past year, which is strong growth. Also, it has seen its operating income increase by 30.81% over the past year, which suggests its operations are becoming much more profitable.

Valuation Model

Key Score

4.00

Good

Management

5.00

Very Good

Growth

1.00

Very Bad

Profitability

2.00

Bad

Fin. Health

4.00

Good

Dividends

--

--

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form PRE 14A

Unknown Form Type

Filed on 2026-03-06 16:55:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-04 19:35:31

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-04 19:35:30

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-04 19:35:28

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-04 19:35:27

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 17:19:43

Form 425

This is a document companies must file to disclose information about mergers between two or more companies

Filed on 2026-03-03 16:57:10

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-27 17:31:09

Form S-4

Registration statement under Securities Act of 1933

Filed on 2026-02-27 16:35:50

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-02-26 17:11:42

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-02-24 16:13:36

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-02-24 16:12:34

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$130.20

82.9%

Avg:

$107.13

50.5%

Low:

$83.83

17.7%

(% change is relative to the current stock price: $71.20)

Analyst Recommendations

Go to Analyst Tab

4.28

Very Good

35%

Strong Buy (14)

57%

Buy (23)

8%

Hold (3)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.bostonscientific.com/en-US/Home.html
Address
300 Boston Scientific Way, Marlborough MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=885725

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

IPO Date

1992-05-19

Industry

Health Care

Total Employees

59,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services